After obtaining an MPharm (Hons) degree from the University of Nottingham in 2003, I spent fourteen months working as a community pharmacist/district manager with Alliance Pharmacy and remain a registered pharmacist with the General Pharmaceutical Council (GPhC).
I obtained my PhD from the University of Nottingham 2009, under the supervision of Prof. Barrie Kellam and Prof. Stephen Hill. The work from my PhD formed the basis for a Wellcome Trust Seeding Drug Discovery project focusing on the lead optimisation of new highly selective beta-blockers, which I continued to work on for three years as a post-doctoral research fellow.
I subsequently spent two and a half years as a senior research fellow with Prof. Peter Scammells at the Monash Institute of Pharmaceutical Sciences (Melbourne, Australia) working on a variety of projects.
I returned to Nottingham in 2014, after appointment as an Assistant Professor in Medicinal Chemistry, within the School of Pharmacy. In addition to my research interests, I teach on the undergraduate Pharmacy and Pharmaceutical Scienceprogrammes and am the Course Director for both Postgraduate-Taught programmes offered by the school:
- MSc Drug Discovery and Pharmaceutical Sciences
- MSc Drug Discovery and Pharmaceutical Sciences with Industrial Training (2-year)
Undergraduate - MPharm:
B33RPJ (Research Project)
PHAR4012/B34ADD (Advanced Drug Discovery)
PHAR4028 (Current Topics in Pharmaceutical Sciences)
Postgraduate - MSc Drug Discovery and Pharmaceutical Sciences:
PHAR4006/B34FDD - Fundamentals of Drug Discovery
PHAR4008/B34DD1 - Drug Discovery and Development 1
PHAR4010/B34RES - Research Project
PHAR4006/B34FDD - Fundamentals of Drug Discovery (30 credits)
PHAR4010/B34RES - Research Project (60 credits)
PHAR4026 - Industrial Research Project with Training in Scientific Research (120 credits)
PHAR4028 - Current Topics in Pharmaceutical Sciences (30 credits)
My group has an interest in the application of synthetic organic and medicinal chemistry. This involves the design, synthesis, purification and characterisation of small molecules and peptides in the… read more
TIM J. FYFE, BARRIE KELLAM, SHAILESH N. MISTRY, PETER J. SCAMMELLS, J. ROBERT LANE and BEN CAPUANO, 2019. Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D2 receptor European Journal of Medicinal Chemistry. 168, 474 - 490 TIM J. FYFE, BARRIE KELLAM, DAVID A. SYKES, BEN CAPUANO, PETER J. SCAMMELLS, J. ROBERT LANE, STEVEN J. CHARLTON and SHAILESH N. MISTRY, 2019. Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor Journal of Medicinal Chemistry. 62(21), 9488-9520 FYFE, TJ, ZARZYCKA, B, LIM, HD, KELLAM, B, MISTRY, SN, KATRICH, V, SCAMMELLS, PJ, LANE, JR and CAPUANO, B, 2018. A Thieno[2,3-d]pyrimidine Scaffold is a Novel Negative Allosteric Modulator of the Dopamine D2 Receptor Journal of Medicinal Chemistry. 62(1), 174-206
VAN DER WESTHUIZEN, ET, SPATHIS, A, KHAJEHALI, E, JORG, M, MISTRY, SN, CAPUANO, B, TOBIN, AB, SEXTON, PM, SCAMMELLS, PJ, VALANT, C and CHRISTOPOULOS, A, 2018. Assessment of the molecular mechanisms of action of novel 4-phenylpyridine-2-one and 6-phenylpyrimidin-4-one allosteric modulators at the M1 muscarinic acetylcholine receptor Molecular Pharmacology.
My group has an interest in the application of synthetic organic and medicinal chemistry. This involves the design, synthesis, purification and characterisation of small molecules and peptides in the pursuit of novel drug discovery, or the development of tool compounds. In particular, we have a focus on developing allosteric, orthosteric and bitopic ligands for G Protein-coupled receptors (GPCRs) and other proteins to understand better how these proteins work. Current GPCR targets of interest are:
- C-X-C Chemokine receptor type 2 (CXCR2)
- D2 Dopamine receptor
- M1 Muscarinic receptor
- Nociceptin receptor (NOPR)
- EP2 Prostaglandin receptor
My previous work within the drug discovery team at Nottingham focused on the discovery and development of novel, highly selective beta-blockers. Taking compounds discovered during my PhD, we undertook an intensive lead-optimisation programme to develop a number of advanced leads with an improved selectivity profile and ADMET properties compared to existing beta blockers.
At Monash university, I was involved in the discovery and development of novel allosteric ligands for a number of G protein-coupled receptor (GPCR) targets, including:
- M1 muscarinic acetylcholine receptor
- D2 dopamine receptor
- Calcium-sensing receptor
Through collaboration, we combined our ligand-based approaches with structural and computational techniques, to gain insight into both the locality and mechanism of allosteric interaction at different GPCRs.
Other areas of research include the development of novel inhibitors, targeting multiple enzymes in the parasite Plasmodium falciparum, as a new strategy in the fight against malaria.